Literature DB >> 16168294

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

Enrica Perugini1, Pier Luigi Guidalotti, Fabrizio Salvi, Robin M T Cooke, Cinzia Pettinato, Letizia Riva, Ornella Leone, Mohsen Farsad, Paolo Ciliberti, Letizia Bacchi-Reggiani, Francesco Fallani, Angelo Branzi, Claudio Rapezzi.   

Abstract

OBJECTIVES: We investigated the diagnostic accuracy of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy for differentiation of monoclonal immunoglobulin light-chain (AL) and transthyretin (TTR)-related cardiac amyloidosis.
BACKGROUND: Differential diagnosis between TTR-related and AL amyloidosis is often complex and time-consuming.
METHODS: Patients under routine observation with TTR-related/AL systemic amyloidosis and echocardiographic evidence of cardiac involvement were studied with 99mTc-DPD scintigraphy.
RESULTS: Patients with cardiac involvement of TTR-related (group A; n = 15) and AL (group B; n = 10) etiology were comparable for left ventricular mass and renal function. Heart and heart/whole-body tracer retention were significantly higher (p < 0.05) in group A as compared with group B and with 10 unaffected controls. At visual scoring, cardiac 99mTc-DPD uptake was present in all group A patients and absent in all group B patients; thus, using genotyping/immunohistochemistry as the reference technique, the accuracy of 99mTc-DPD scintigraphy for distinction of TTR-related and AL etiology was 100%. Cardiac 99mTc-DPD uptake was also absent among unaffected controls. Using echocardiography as the reference standard for recognition of cardiac involvement, sensitivity and specificity of scintigraphy were both 100% for group A patients; in group B, sensitivity was 0% and specificity was 100% (accuracy, 50%). Eleven patients with myocardial 99mTc-DPD uptake underwent 99mTc-methylene diphosphonate (99mTc-MDP) scintigraphy; all patients showed a 99mTc-MDP myocardial visual score of 0.
CONCLUSIONS: Etiology is a third major cause--in addition to type of organ-involved (soft-tissue/heart) and tracer type--of scintigraphic variability in cardiac amyloidosis. This is a highly relevant consideration for future studies. We conclude that 99mTc-DPD scintigraphy is a useful step in the workup of the differential diagnosis of TTR versus AL etiology in patients with documented cardiac amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168294     DOI: 10.1016/j.jacc.2005.05.073

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  181 in total

1.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

Review 2.  Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Authors:  Toru Kubo; Hiroaki Kitaoka
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

3.  Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.

Authors:  Andrew J Einstein; Igor Shuryak; Adam Castaño; Akiva Mintz; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2018-05-30       Impact factor: 5.952

Review 4.  Novel Approaches for the Management of AL Amyloidosis.

Authors:  Nisha S Joseph; Jonathan L Kaufman
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 5.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

6.  Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis.

Authors:  Sarah Pradel; Stéphanie Brun; Gérard Victor; Pierre Pascal; Pauline Fournier; David Ribes; Yoan Lavie-Badie; Michel Galinier; Didier Carrié; Isabelle Berry; Olivier Lairez
Journal:  J Nucl Cardiol       Date:  2018-06-07       Impact factor: 5.952

Review 7.  2021 Advocacy Statements for the Role of 99mTc-Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis: A Report of the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.

Authors:  Yih-Hwen Huang; Yen-Hung Lin; Ruoh-Fang Yen; Charles Jia-Yin Hou; Shan-Ying Wang; Shih-Chuan Tsai; Kung-Chu Ho; Ming-Hsien Lin; Chin-Ho Tsao; Chih-Yung Chang; Jin-Long Huang; Mei-Fang Cheng; Yen-Wen Wu
Journal:  Acta Cardiol Sin       Date:  2021-05       Impact factor: 2.672

8.  Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Shahzad Ahmad; Ricardo Nieves; Yvonne S Eisele; William Follansbee; Amy Brownell; Timothy C Wong; Erik Schelbert; Prem Soman
Journal:  Circ Cardiovasc Imaging       Date:  2020-02-17       Impact factor: 7.792

Review 9.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

10.  Tc-99m Radiolabeled Peptide p5 + 14 is an Effective Probe for SPECT Imaging of Systemic Amyloidosis.

Authors:  Stephen J Kennel; Alan Stuckey; Helen P McWilliams-Koeppen; Tina Richey; Jonathan S Wall
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.